US pharmaceutical giant Pfizer said Tuesday it will sell about 500 of its vaccines and drugs at cost to poorer countries, expanding on a previous commitment to reduce global health inequalities.
In May 2022, the group announced in an initiative announced at the Davos Economic Forum that it would supply 23 vaccines and patented drugs available in the US and the European Union to 45 poor countries. 1.2 billion people.
“Pfizer will now expand its offering under the agreement to include generic products, bringing its total product offering from 23 to approximately 500,” the company said in a statement.
All of these products are owned by Pfizer worldwide, she said.
Selling at cost means that only production costs and shipping costs will be charged in the respective countries.
Among the medicines and vaccines under consideration are products “that treat or prevent many of the biggest infectious and noncommunicable disease threats facing low-income countries today,” such as antibiotics or chemotherapy, the business added.
“We believe that this expansion of our product offering, combined with ongoing efforts to remove barriers that restrict or prevent access, will help us realize and even accelerate our vision of a world where the whole world has access to medicines and vaccines. essential for a longer, healthier life,” Pfizer CEO Albert Burla said in a statement.
As Pfizer launches other drugs and vaccines, they will also be included in the agreement.